10,000
Participants
Start Date
July 26, 2018
Primary Completion Date
May 31, 2019
Study Completion Date
September 9, 2019
OraQuick
Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
District of Butha-Buthe, Butha-Buthe
District of Mokhotlong, Mokhotlong
SolidarMed
OTHER
Ministry of Health, Lesotho
OTHER_GOV
University of Basel
OTHER
University Hospital, Basel, Switzerland
OTHER
Tracy Glass
OTHER